GlassScriptPhysician profile
Rudy Haddad
NPI 1861470023
$26,036.95
in general payments reported to CMS, 2019-2025
33 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,771 · 2020: $9,327 · 2021: $6,766 · 2022: $2,106 · 2023: $1,644 · 2024: $1,664 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,066.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,672.61 | 2019-2025 | Farxiga, Wainua |
| Abbott Laboratories | $3,708.31 | 2019-2025 | Ultreon, Dragonfly Opstar, Cardiomems |
| Abiomed | $1,515.35 | 2019-2025 | Impella |
| Medtronic, INC. | $1,329.84 | 2021-2025 | Corevalve Evolut R, Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,265.48 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $728.47 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $627.54 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $594.47 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $451.87 | 2021-2025 | |
| Amarin Pharma, INC. | $341.73 | 2019-2022 | |
| Edwards Lifesciences Corporation | $314.08 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $191.95 | 2020-2022 | |
| Amgen INC. | $164.22 | 2019-2023 | Repatha |
| Cook Medical LLC | $134.11 | 2021-2022 | |
| Heartflow, INC. | $128.91 | 2021-2023 | Ffrct |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $114.00 | 2019-2024 | Watchman Access System |
| Novo Nordisk INC | $106.14 | 2024-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $95.74 | 2021-2024 | Verquvo, Belsomra |
| Sanofi-Aventis U.S. LLC | $66.28 | 2019 | |
| Pfizer INC. | $65.06 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.35 | 2019-2025 | Jardiance |
| Inari Medical, INC. | $54.93 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cordis US Corp. | $44.54 | 2025 | Precise Pro Rx, Mynx Control Venous |
| Shockwave Medical, INC | $41.76 | 2022-2025 | |
| Terumo Medical Corporation | $36.45 | 2022-2023 | Glidewire, Angio-Seal, Optitorque |
| Acist Medical Systems, INC. | $32.77 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $29.85 | 2024 | Arcalyst |
| Biotronik INC. | $26.73 | 2023 | Recross |
| Vital Connect, INC | $26.18 | 2023 | Vitalpatch Rtm |
| Bard Peripheral Vascular, INC. | $22.55 | 2022 | |
| Chiesi USA, INC. | $15.38 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.26 | 2019 | |
| Cardiovascular Systems INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudy Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.